Macrolide antibiotics for non-cystic fibrosis bronchiectasis (Protocol). by Kelly, Carol et al.
Cochrane Database of Systematic Reviews
Macrolide antibiotics for non-cystic fibrosis bronchiectasis
(Protocol)
Kelly C, Evans DJ, Chalmers JD, Crossingham I, Spencer S, Relph N, Felix LM, Milan SJ
Kelly C, Evans DJ, Chalmers JD, Crossingham I, Spencer S, Relph N, Felix LM, Milan SJ.
Macrolide antibiotics for non-cystic fibrosis bronchiectasis.
Cochrane Database of Systematic Reviews 2016, Issue 10. Art. No.: CD012406.
DOI: 10.1002/14651858.CD012406.
www.cochranelibrary.com
Macrolide antibiotics for non-cystic fibrosis bronchiectasis (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iMacrolide antibiotics for non-cystic fibrosis bronchiectasis (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Protocol]
Macrolide antibiotics for non-cystic fibrosis bronchiectasis
Carol Kelly1, David J Evans2, James D Chalmers3, Iain Crossingham4, Sally Spencer1, Nicola Relph5, Lambert M Felix1, Stephen J
Milan6
1Faculty of Health and Social Care, Edge Hill University, Ormskirk, UK. 2Thoracic Medicine, Hemel Hempstead Hospital, Hemel
Hempstead, UK. 3University of Dundee, Ninewells Hospital and Medical School, Dundee, UK. 4East Lancashire Hospitals NHS
Trust, Blackburn, UK. 5Physical Activity and Sport, Edge Hill University, Ormskirk, UK. 6Lancaster HealthHub, Lancaster University,
Lancaster, UK
Contact address: Sally Spencer, Faculty of Health and Social Care, Edge Hill University, Ormskirk, UK. spencesa@edgehill.ac.uk.
Editorial group: Cochrane Airways Group.
Publication status and date: New, published in Issue 10, 2016.
Citation: Kelly C, Evans DJ, Chalmers JD, Crossingham I, Spencer S, Relph N, Felix LM, Milan SJ. Macrolide antibi-
otics for non-cystic fibrosis bronchiectasis. Cochrane Database of Systematic Reviews 2016, Issue 10. Art. No.: CD012406. DOI:
10.1002/14651858.CD012406.
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To determine the impact of macrolide antibiotics in the treatment of adults and children with non-cystic fibrosis bronchiectasis.
B A C K G R O U N D
Description of the condition
Bronchiectasis is a chronic respiratory disease characterised by ab-
normal and irreversible dilatation and distortion of the smaller
airways (Pasteur 2010). Bacterial colonisation of the damaged air-
ways leads to chronic cough and sputum production, often with
breathlessness and with further structural damage to the airways.
Diagnosis is by computed tomography (CT) scanning of the chest
when the appropriate clinical symptoms are identified (Chang
2010) but asymptomatic radiological evidence of bronchiectasis is
possible (Kwak 2010).
Bronchiectasis has many causes, generally involving either major
or repeated insults to the lungs. Severe infections including pneu-
monia, tuberculosis and pertussis may cause bronchiectasis, par-
ticularly if they occur during childhood whilst lungs are still devel-
oping. Connective tissue disorders and defects in the immune sys-
tem are other common causes of bronchiectasis, butmany cases are
idiopathic. Cystic fibrosis leads to a severe, progressive bronchiec-
tasis and is usually considered a separate entity from ’non-cystic fi-
brosis’ bronchiectasis. This review will exclude bronchiectasis sec-
ondary to cystic fibrosis.
Estimates of the prevalence of bronchiectasis vary considerably.
Although it has previously been considered a relatively rare disease
(Kolbe 1996), more recent studies have suggested an increasing
prevalence, particularly in those over 75 years (Weycker 2005),
and higher prevalence rates in low-income and middle-income
countries (Habesoglu 2011). Prevalence rates per 100,000 were
estimated at 0.5 in Finland and 3.7 in New Zealand though these
data are more than 10 years old (European Lung White Book
2013). Higher prevalence rates are associated with the over 60s,
women, and vary by ethnicity (Chang 2003; Seitz 2012). Recent
data suggest that incidence andprevalence in theUKmaybe higher
than previously estimated (Quint 2016). Over a nine-year period
to 2013, point prevalence rates per 100,000 rose from 350.5 to
1Macrolide antibiotics for non-cystic fibrosis bronchiectasis (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
566.1 in women and from 301.2 to 485.5 in men. This reflects
an increase of more than 60% with approximately 263,000 adults
living with bronchiectasis in 2013. Similarly, the incidence rates
per 100,000 person-years rose from 21.2 to 35.2 in women and
from 18.2 to 26.9 in men, a 63% increase in new cases to over
15,000 in 2013. However, these increases may be due to improved
diagnosis resulting from easier access to high quality CT scanners,
rather than a true rise in prevalence (Goeminne 2016).
Mortality rates in England andWales rose by 3% per year between
2001 to 2007 (Roberts 2010), and hospitalisations also increased
by 3% per year over a nine-year period in the US (Seitz 2010).
Average mortality rates per 100,000 general population in Europe
are estimated at 0.3 in 27 of the 28 countries in the EU (ranging
from 0.01 in Germany to 1.18 in the UK) and 0.2 in nine non-EU
countries (ranging from 0.01 in Azerbaijan to 0.67 in Kyrgyzstan),
based on 2005 to 2009 data (European Lung White Book 2013).
The recent UK study reported higher age-adjusted mortality rates,
with estimates 2.26 times higher in women and 2.14 times higher
in men compared to the general population (Quint 2016).
Description of the intervention
Chronic airway infection with pathogens such as Pseudomonas
aeruginosa and Haemophilus influenzae and neutrophil-mediated
airway inflammation are the key drivers of disease progression and
poor outcome in bronchiectasis (Chalmers 2012; Chalmers 2014;
Finch 2015). Long-term antibiotic therapy is therefore often pre-
scribed with the intention of suppressing bacterial load and reduc-
ing airway inflammation (Chalmers 2012). This in turn aims to
reduce exacerbations, improve symptoms and improve quality of
life (Haworth 2014). Prolonged antibiotic treatment can be ad-
ministered in the form of oral or inhaled antibiotics. Inhaled an-
tibiotics have the advantage of delivering a higher dose of the drug
directly to the site of bronchiectasis infection, with less potential
for collateral damage and resistance, however, they are often time
consuming to administer (Brodt 2014). Oral antibiotics by con-
trast are typically cheaper and easier to administer than inhaled
antibiotics.
Oral antibiotics may be given at lower dose than those used to
treat acute infections, with the aim to reduce adverse effects and
promote compliance (Haworth 2014). Macrolide antibiotics are
antibacterial agents with anti-inflammatory and immunomodu-
latory properties (Haworth 2014). Long-acting macrolide antibi-
otics such as azithromycin can be given intermittently rather than
requiring daily dosing. Penicillins, tetracyclines and macrolides
have all been tested as prolonged therapy in bronchiectasis (Pasteur
2010). National guidelines for bronchiectasis, such as those from
the British Thoracic Society suggest considering the use of long-
term antibiotic treatment in patients with three or more exacer-
bations per year (Pasteur 2010).
Long-term use of macrolides in bronchiectasis is supported by
their ease of administration, their effectiveness in cystic fibrosis
and other neutrophilic lung diseases and their reported anti-in-
flammatory properties (Saiman 2003). Balanced against this is the
potential for macrolides to induce antibiotic resistance, the poten-
tial for antibiotic-related adverse effects, hearing impairment and
cardiotoxicity (Serisier 2013).
How the intervention might work
Exacerbations, symptoms and quality of life are directly linked
to bacterial infection and airway inflammation in bronchiectasis
(Chalmers 2012; Chalmers 2014). Macrolides are given as both
antibacterial and anti-inflammatory drugs, although it is unclear
which of these properties is primarily responsible for the clinical
effect observed in cystic fibrosis or bronchiectasis. Macrolides bind
reversibly to the 50s ribosomal subunit, preventing bacterial pro-
tein synthesis (Haworth 2014). They therefore have broad activity
against Gram-positive organisms such as Staphylococci and Strep-
tococci, and a degree of activity against Gram-negative organisms
such as Haemophili. Interestingly, they show no bacteriocidal ac-
tivity against P aeruginosa but may modify virulence by interfering
with quorum sensing and virulence factors (Kohler 2010).
The anti-inflammatory effects of macrolides have been known
for decades, classically demonstrated in their effectiveness against
diffuse panbronchiolitis (Amsden 2005). Macrolides contain a
macrocytic lactone ring that is thought to be responsible for
the majority of the anti-inflammatory effects (Haworth 2014).
Macrolides are classified according to the number of lactone rings
as 14-, 15- and 16-member ring macrolides. Macrolides have po-
tentially beneficial effects at every level of the ’vicious cycle’ of
bronchiectasis. They reduce the secretion of pro-inflammatory cy-
tokines from epithelial cells, inhibit leukocyte recruitment to the
airway, inhibit neutrophil activation and reduce oxidative stress
(Zarogoulidis 2012).
Thus potential benefits of macrolides will include the suppression
of bacterial infection, leading to reduced exacerbations, reduced
cough and sputum production and improved lung function and
quality of life.
Why it is important to do this review
Non-cystic fibrosis bronchiectasis is associated with a mortal-
ity rate more than twice that of the general population; 2.26
times higher in women and 2.14 times higher in men (Quint
2016). Frequent exacerbations impair quality of life and lead to
progressive lung damage with permanent loss of lung function
(Martínez-García 2007). Drug interventions which are effective
in reducing the frequency of exacerbations should therefore be of
both short- and long-term benefit to patients with bronchiectasis.
ACochrane reviewof short-term antibiotics showed therewas little
evidence on which to base a recommendation, with one small trial
showing evidence of global improvement and pathogen eradica-
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tion in sputum (Wurzel 2011). A furtherCochrane review of long-
term antibiotic therapy included 18 trials of moderate quality and
provided evidence of a reduction in exacerbation frequency and
hospitalisation, but an increase in drug resistance (Hnin 2015).
Neither of these reviews examined effects by class of antibiotics and
did not specifically subgroup by macrolide therapy. A Cochrane
overview concluded that further evidence is required on the ef-
ficacy of antibiotics in terms of eradication of specific bacterial
colonisation and the extent of antibiotic resistance (Welsh 2015).
The importance of this question was further reinforced by recent
recommendations from the European Task Force on bronchiecta-
sis that named research on macrolide therapy as one of the key pri-
orities in bronchiectasis (Aliberti 2016). Macrolides may poten-
tially reduce bronchiectasis exacerbations. Given their drawbacks,
particularly cardiac toxicity (Ray 2012) and the potential for se-
lecting for antibiotic-resistant organisms (Leclercq 2002), robust
evidence for their effectiveness is needed for them to be used with
confidence for this indication.
This review is being conducted alongside two other closely re-
lated reviews: ’Dual antibiotics for non-cystic fibrosis bronchiec-
tasis’ and’Head to head trials of antibiotics for non-cystic fibrosis
bronchiectasis.’
O B J E C T I V E S
To determine the impact of macrolide antibiotics in the treatment
of adults and children with non-cystic fibrosis bronchiectasis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Wewill include randomised controlled trials (RCTs) of at least four
weeks duration. We will include cross-over studies, but will only
use data from the first pre-cross-over phase to eliminate potentially
irreversible carry-over effects (e.g. antibiotic resistance). We will
include studies reported as full-text, those published as abstract
only, and unpublished data.
Types of participants
We will include adult and paediatric participants diagnosed with
bronchiectasis by bronchography, plain film chest radiograph, or
high-resolution computed tomography who report daily sputum
expectoration for at least three months. We will not exclude par-
ticipants diagnosed by radiography alone. When a study includes
participants with different respiratory conditions, we will only in-
clude that study if there is a separate subgroup analysis conducted
for participantswith bronchiectasis. Studieswill be excluded if par-
ticipants have been receiving continuous or high-dose antibiotics
immediately before the study, or if they have received a diagno-
sis of cystic fibrosis, sarcoidosis or allergic bronchopulmonary as-
pergillosis. We will define the paediatric population as those from
six months to 18 years of age.
Types of interventions
We will include studies comparing macrolide antibiotics with
placebo, standard care or non-macrolide antibiotics in the long-
term management of stable bronchiectasis. These different com-
parisons will be considered separately. We will exclude studies
looking at short-term macrolides for the treatment (as opposed to
prevention) of exacerbations of bronchiectasis.
Types of outcome measures
Where possiblewewill assess exacerbation andhospitalisation rates
at 12 months. We will estimate annual rates in studies reporting
shorter follow-up times. We will collect outcome data at a range of
follow-up points that will best reflect the available evidence from
included studies, e.g. end of study, end of follow-up, change from
baseline.
Primary outcomes
1. Exacerbations (defined using study authors’ criteria).
2. Hospitalisation (defined using study authors’ criteria).
3. Adverse events and serious adverse events using the
definitions from Hansen 2015 as follows.
i) Adverse events are unwanted outcomes undetectable
by the patient; usually identified by laboratory tests (e.g.
biochemical, haematological, immunological, radiological,
pathological tests) or by clinical investigations (e.g.
gastrointestinal endoscopy, cardiac catheterisation).
ii) Serious adverse events are those that result in death or
life-threatening events; requirement for hospitalisation or
prolongation of existing hospitalisation; persistent or significant
disability; or congenital anomalies, or are events that are
considered medically important.
Secondary outcomes
1. Sputum volume and purulence.
2. Measures of lung function (e.g. forced expiratory volume in
one second (FEV1)).
3. Systemic markers of infection (e.g. leucocyte count, C-
reactive protein (CRP), erythrocyte sedimentation rate (ESR)).
4. Adverse events (e.g. cardiac arrhythmias, gastrointestinal
symptoms, hearing impairment).
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5. Mortality (we will extract and report whether this is defined
as all-cause or bronchiectasis-related in the individual studies).
6. Emergence of resistance to antibiotics.
7. Exercise capacity (e.g. the Six-Minute Walk Distance test
(6MWD)).
8. Quality of life (e.g. St George Respiratory Questionnaire
(SGRQ)).
Reporting one or more of the outcomes listed here in the study
will not be an inclusion criterion for the review.
Search methods for identification of studies
Electronic searches
We will identify studies from the Cochrane Airways Group’s Spe-
cialised Register (CAGR), which is maintained by the Information
Specialist for the Group. The Register contains trial reports iden-
tified through systematic searches of bibliographic databases in-
cluding theCochrane Central Register of Controlled Trials (CEN-
TRAL), MEDLINE, Embase, CINAHL (Cumulative Index to
Nursing and Allied Health Literature), AMED (Allied and Com-
plementary Medicine), and PsycINFO, and handsearching of res-
piratory journals and meeting abstracts (please see Appendix 1 for
further details). We will search all records in the CAGR using the
search strategy in Appendix 2.
We will also conduct a search of the US National Insti-
tutes of Health Ongoing Trials Register ClinicalTrials.gov (
www.clinicaltrials.gov) and the World Health Organization
International Clinical Trials Registry Platform (apps.who.int/
trialsearch).
We will search all databases from their inception to the present,
and we will impose no restriction on language of publication.
Searching other resources
We will check reference lists of all primary studies and review ar-
ticles for additional references. We will search relevant manufac-
turers’ websites for study information.
We will search for errata or retractions from included studies pub-
lished in full-text on PubMed (www.ncbi.nlm.nih.gov/pubmed)
and report the date this was done within the review.
Data collection and analysis
Selection of studies
Two review authors (James Chalmers (JC) and David Evans (DE)
will independently screen titles and abstracts for inclusion of all
the potential studies we identify as a result of the search and code
them as ’retrieve’ (eligible or potentially eligible/unclear) or ’do not
retrieve’. We will retrieve the full-text study reports/publication
and two review authors (JC and DE) will independently screen
the full-text, identify studies for inclusion, and identify and record
reasons for exclusion of the ineligible studies. We will resolve any
disagreement through discussion or, if required, we will consult a
third review author (Sally Spencer (SS) or Stephen J Milan (SJM).
Wewill identify and exclude duplicates and collatemultiple reports
of the same study so that each study rather than each report is the
unit of interest in the review. We will record the selection process
in sufficient detail so as to complete a PRISMA flow diagram and
Characteristics of excluded studies table (Moher 2009).
Data extraction and management
We will use a data collection form for study characteristics and
outcome data which has been piloted on at least one study in the
review. One review author (Lambert Felix (LF) will extract study
characteristics from included studies. We will extract the following
study characteristics.
1. Methods: study design, total duration of study, details of
any ’run in’ period, number of study centres and location, study
setting, withdrawals, and date of study.
2. Participants: number, mean age, age range, gender, severity
of condition, diagnostic criteria, baseline lung function, smoking
history, inclusion and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for study, and notable conflicts of interest of
study authors.
Two review authors (LF and Carol Kelly (CK) will independently
extract outcome data from the included studies. We will note in
the ’Characteristics of included studies’ table if outcome data were
not reported in a usable way. We will resolve disagreements by
consensus or by involving a third review author (SS or SJM). One
review author (LF) will transfer data into the Review Manager
(RevMan 2014) file. We will double-check that data are entered
correctly by comparing the data presented in the systematic review
with the study reports. A second review author (CK) will spot-
check study characteristics for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (Nicola Relph (NR) and LF) will indepen-
dently assess risk of bias for each study using the criteria outlined
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). We will resolve any disagreements by discussion
or by involving another review author (SS or SJM). We will assess
the risk of bias according to the following domains.
1. Random sequence generation.
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2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We will grade each potential source of bias as high, low or unclear
and provide a quote from the study report together with a justifi-
cation for our judgement in the ’Risk of bias’ table. We will sum-
marise the risk of bias judgements across different studies for each
of the domains listed. We will consider blinding separately for dif-
ferent key outcomes where necessary (e.g. for unblinded outcome
assessment, risk of bias for all-cause mortality may be very differ-
ent than for a patient-reported pain scale). Where information on
risk of bias relates to unpublished data or correspondence with a
study author, we will note this in the ’Risk of bias’ table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Assessment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and report any deviations form it in the ’Differences between pro-
tocol and review’ section of the systematic review.
Measures of treatment effect
We will analyse dichotomous data as odds ratios and continuous
data as mean difference or standardised mean difference. We will
analyse hospitalisation and exacerbation rates as rate ratios where
possible. We will enter data presented as a scale with a consistent
direction of effect.
We will undertake meta-analyses only where this is meaningful i.e.
if the treatments, participants and the underlying clinical question
are similar enough for pooling to make sense.
We will narratively describe skewed data reported as medians and
interquartile ranges.
Where multiple trial arms are reported in a single trial, we will
include only the relevant arms. If two comparisons (e.g. drug A
versus placebo and drug B versus placebo) are combined in the
same meta-analysis, we will halve the control group to avoid dou-
ble-counting.
Unit of analysis issues
In all included studies the unit of analysis will be the participant.
In terms of exacerbation rates and admission rates we plan to focus
on the number of events experienced by the participant during
the trial. Where cross-over trials are included we will only use data
from the first pre-cross-over phase to minimise potential bias from
carry-over effects.
Dealing with missing data
We will contact investigators or study sponsors in order to verify
key study characteristics and obtain missing numerical outcome
data where possible (e.g. when a study is identified as abstract
only). Where this is not possible, and the missing data are thought
to introduce serious bias, we will explore the impact of including
such studies in the overall assessment of results by a sensitivity
analysis.
Assessment of heterogeneity
We will use the I2 statistic to measure heterogeneity among the
studies in each analysis. If we identify substantial heterogeneity we
will report it and explore possible causes by prespecified subgroup
analysis.
Assessment of reporting biases
If we are able to pool more than 10 studies, we will create and
examine a funnel plot to explore possible small study and publi-
cation biases.
Data synthesis
Outcomes will be included in meta-analyses where the study de-
signs, interventions and outcomes are similar. Where substantial
heterogeneity (> 50%) is identified we will report outcomes in the
text, giving direction and size of the effect along with the strength
of the evidence (risk of bias). It is likely that antibiotic studies
will vary by population, design and outcomes, therefore meta-
analysis using a random-effects model would be most appropri-
ate. However, where there are few studies or the effects of inter-
ventions across studies are not randomly distributed (for example,
with publication bias), the estimates from a random-effects model
may be unreliable or biased. It is likely that this review will only
include a small number of low powered studies, therefore we will
use a fixed-effect model, reported with 95% confidence intervals
(CI), and evaluate the impact of model choice using a sensitivity
analysis. We will synthesise and report dichotomous and contin-
uous data separately for each outcome (e.g. exacerbation/no ex-
acerbation or exacerbation duration). Where end-of-study point
estimates and change from baseline scores are reported we will
analyse these separately.
’Summary of findings’ table
We will create a ’Summary of findings’ table using the following
primary and secondary outcomes: exacerbations, hospitalisation,
serious adverse events, deaths, quality of life. We will use the five
GRADE considerations (study limitations, consistency of effect,
imprecision, indirectness and publication bias) to assess the quality
of a body of evidence as it relates to the studies which contribute
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data to the meta-analyses for the prespecified outcomes. We will
use methods and recommendations described in Section 8.5 and
Chapter 12 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011) using GRADEproGDT software (
GRADEproGDT). We will justify all decisions to downgrade or
upgrade the quality of studies using footnotes and we will make
comments to aid the reader’s understanding of the review where
necessary.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses.
1. Children versus adults.
2. Macrolides versus other classes of long-term antibiotics.
3. Type of macrolide.
4. Dose and frequency.
5. Duration.
We will use the following outcomes in subgroup analyses.
1. Exacerbations.
2. Hospitalisation.
3. Serious adverse events.
We will use the formal test for subgroup interactions in Review
Manager (RevMan 2014).
Sensitivity analysis
We plan to evaluate the effects of methodological study quality by
removing those at high or unclear risk of bias for the domains of
random sequence generation or allocation concealment.
We will also conduct a separate analysis including only those com-
paring macrolides with a placebo-controlled group.
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group’s Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL (the Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
Embase (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
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Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Bronchiectasis search
1. exp Bronchiectasis/
2. bronchiect$.mp.
3. bronchoect$.mp.
4. kartagener$.mp.
5. (ciliary adj3 dyskinesia).mp.
6. (bronchial$ adj3 dilat$).mp.
7. or/1-6
Filter to identify randomised controlled trials (RCTs)
1. exp “clinical trial [publication type]”/
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter (Lefebvre 2011) are adapted to identify trials in other electronic databases.
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Appendix 2. Search strategy to identify relevant trials from the CAGR
#1 BRONCH:MISC1
#2 MeSH DESCRIPTOR Bronchiectasis Explode All
#3 bronchiect*
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Macrolides Explode 1 2 3
#6 macrolide*
#7 azithromycin*
#8 clarithromycin*
#9 erythromycin*
#10 roxithromycin*
#11 spiramycin*
#12 telithromycin*
#13 troleandomycin*
#14 Josamycin*
#15 Midecamycin*
#16 Oleandomycin*
#17 Solithromycin*
#18 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17
#19 #4 AND #18
(Note: in search line #1, MISC1 denotes the field in the record where the reference has been coded for condition, in this case,
bronchiectasis)
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